載入中
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
前收盤價
US$0.4857
+US$0.0147 · +3.12%
盤中時間採用ET。市場資料可能有所延遲。
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
日內區間
目前US$0.4857
52週區間
目前US$0.4857
盤中時間採用ET。市場資料可能有所延遲。
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
日內區間
目前US$0.4857
52週區間
目前US$0.4857
營業利益
淨利
| 項目（USD） | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 2.27萬 USD | — | 2.17萬 USD | 1.78萬 USD | — |
| 毛利 | −2.27萬 USD | — | −2.17萬 USD | −1.78萬 USD | −5671 USD |
| 研究與開發 | 62.55萬 USD | 22.37萬 USD | 24.81萬 USD | 24.79萬 USD | 25.61萬 USD |
| 銷售、一般及管理費用 | 1753.74萬 USD | 5705.44萬 USD | 128.8萬 USD | 152.87萬 USD | 172.9萬 USD |
| 營業費用 | 1818.56萬 USD | 5727.81萬 USD | 151.4萬 USD | 175.9萬 USD | 198.5萬 USD |
| 利息收入 | 161 USD | 9 USD | 60 USD | 36 USD | 5613 USD |
| 利息支出 | 43.05萬 USD | 56.38萬 USD | 66.58萬 USD | 53.28萬 USD | 56.88萬 USD |
| 折舊和攤銷 | 2.27萬 USD | 2.02萬 USD | 2.17萬 USD | 2.29萬 USD | 5671 USD |
| 營業利益 | −1818.56萬 USD | −5727.81萬 USD | −153.6萬 USD | −177.7萬 USD | −199.1萬 USD |
| 淨利 | −1886.27萬 USD | −5892.33萬 USD | −182.1萬 USD | −266.1萬 USD | −265.8萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年5月18日 | 1:25 | — | — |
股票分割 | 2025年1月29日 | 1:60,000 | — | — |
股票分割 | 2023年5月23日 | 1:1,000 | — | — |
股票分割 | 2020年11月19日 | 1:1,000 | — | — |
股票分割 | 2019年6月24日 | 1:500 | — | — |
股票分割 | 2017年4月20日 | 1:250 | — | — |
已生效 2026年5月18日
1:25
已生效 2025年1月29日
1:60,000
已生效 2023年5月23日
1:1,000
已生效 2020年11月19日
1:1,000
已生效 2019年6月24日
1:500
已生效 2017年4月20日
1:250
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
